" class="no-js "lang="en-US"> MTA's Pharmapack Europe 2023 Highlight Reel
Thursday, March 23, 2023

Breaking News

Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application Morphimmune Appoints Dr. Clay Siegall Chief Executive Officer and President PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million Medtronic to Boost AI Innovation with New Platform Introduction Ionis Accounces FDA Advisory Committee Voted Unanimously for a Potential Accelerated Approval of Tofersen for SOD1-ALS Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care Maze Therapeutics Announces New Clinical Data Supporting MZE001 as a Potential Treatment for Pompe Disease

February 13 2023

MTA’s Pharmapack Europe 2023 Highlight Reel

Pharmapack Europe 2023 is one of the leading events in the pharmaceutical packaging industry, bringing together key players from across the sector to network, share ideas, and showcase the latest developments in the field. The MTA team headed out to Paris to find out more about what was happening at this event, looking at some of the latest trends and innovations in pharmaceutical packaging, including new materials, technologies, and design strategies.

  1. Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer

    News

     Read more
  2. BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases

    Diseases

     Read more
  3. Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome

    Drug Development

     Read more
  4. Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application

    News

     Read more
  5. Morphimmune Appoints Dr. Clay Siegall Chief Executive Officer and President

    Appointments

     Read more
More On